We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+5.31%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.63B
AUM Growth
-$447M
Cap. Flow
-$292M
Cap. Flow %
-11.12%
Top 10 Hldgs %
36.37%
Holding
119
New
10
Increased
38
Reduced
30
Closed
12

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$30.1M
2
SRRK icon
Scholar Rock
SRRK
+$23.3M
3
THC icon
Tenet Healthcare
THC
+$19.2M
4
FOLD
Amicus Therapeutics
FOLD
+$14M
5
JANX icon
Janux Therapeutics
JANX
+$10.8M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$67.2M
2
HUM icon
Humana
HUM
+$46.9M
3
EXAS
Exact Sciences
EXAS
+$43.4M
4
ALGN icon
Align Technology
ALGN
+$29.1M
5
ISRG icon
Intuitive Surgical
ISRG
+$28.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.8%
2 Consumer Staples 1.85%
3 Financials 0.14%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRTC icon
26
iRhythm Holdings
IRTC
$4.02B
$35.8M 1.36%
397,500
– –
ZLAB icon
27
Zai Lab
ZLAB
$2.62B
$34.2M 1.3%
1,305,337
-10,336
-0.8% -$287K
NUVL
28
DELISTED
Nuvalent
NUVL
$33.7M 1.28%
429,994
– –
MREO
29
Mereo BioPharma
MREO
$45.1M
$33.6M 1.28%
9,599,170
+65,000
+0.7% +$255K
SRRK icon
30
Scholar Rock
SRRK
$6.2B
$31M 1.18%
+716,782
New +$23.3M
CLDX icon
31
Celldex Therapeutics
CLDX
$3.34B
$30.9M 1.18%
1,222,182
+118,404
+11% +$3.22M
PODD icon
32
Insulet
PODD
$9.84B
$29.8M 1.14%
114,250
-19,750
-15% -$4.97M
GPCR icon
33
Structure Therapeutics
GPCR
$3.77B
$29.3M 1.12%
1,080,963
+17,053
+2% +$605K
DXCM icon
34
DexCom
DXCM
$33.1B
$27.5M 1.05%
353,000
-171,000
-33% -$12.7M
AKRO
35
DELISTED
Akero Therapeutics
AKRO
$26.3M 1%
946,499
+13,100
+1% +$397K
EXAS
36
DELISTED
Exact Sciences
EXAS
$25.3M 0.96%
450,000
-697,500
-61% -$43.4M
FOLD
37
DELISTED
Amicus Therapeutics
FOLD
$24.5M 0.93%
2,599,425
+1,349,145
+108% +$14M
INSP icon
38
Inspire Medical Systems
INSP
$1.75B
$24.1M 0.92%
130,000
– –
AZTA icon
39
Azenta
AZTA
$1.53B
$23.8M 0.9%
475,000
-57,500
-11% -$2.62M
EVH icon
40
Evolent Health
EVH
$456M
$23.2M 0.88%
2,060,000
-10,000
-0.5% -$176K
ACHC icon
41
Acadia Healthcare
ACHC
$2.96B
$23.1M 0.88%
583,500
-231,500
-28% -$10.4M
IMVT icon
42
Immunovant
IMVT
$8.18B
$22.5M 0.86%
909,103
-312,206
-26% -$8.86M
WRBY icon
43
Warby Parker
WRBY
$3.2B
$22.3M 0.85%
920,000
-519,050
-36% -$10.6M
VERA icon
44
Vera Therapeutics
VERA
$2.26B
$20.6M 0.79%
487,863
+104,371
+27% +$4.62M
BCRX icon
45
BioCryst Pharmaceuticals
BCRX
$2.46B
$20.1M 0.77%
2,677,996
-944,362
-26% -$7.17M
NAMS icon
46
NewAmsterdam Pharma
NAMS
$3.33B
$19.7M 0.75%
767,522
+414,203
+117% +$8.8M
SMMT icon
47
Summit Therapeutics
SMMT
$11.6B
$18.8M 0.72%
1,054,000
+14,000
+1% +$271K
LFST icon
48
Lifestance Health
LFST
$4.57B
$18.8M 0.72%
2,550,000
-551,000
-18% -$3.95M
LEGN icon
49
Legend Biotech
LEGN
$3.99B
$16.7M 0.63%
512,132
+3,200
+0.6% +$133K
THC icon
50
Tenet Healthcare
THC
$21B
$16.3M 0.62%
+129,200
New +$19.2M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Rock Springs Capital Management held 119 positions worth $2.63B, down 15% from $3.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $292M in Q4 2024, closing 12 positions and reducing 30 holdings. Its most notable exit was Humana, an estimated $46.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Scholar Rock worth $31M.

  • Rock Springs Capital Management's largest Q4 2024 buy was Scholar Rock: 716,782 shares worth $31M.
  • Rock Springs Capital Management added most to Blueprint Medicines in Q4 2024, an estimated $30.1M increase.
  • Rock Springs Capital Management's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $67.2M.
  • Rock Springs Capital Management fully exited Humana in Q4 2024, selling an estimated $46.9M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $2.63B portfolio in Q4 2024.
  • Rock Springs Capital Management opened 10 new positions and closed 12 in Q4 2024.
  • Rock Springs Capital Management's portfolio value fell 15% quarter-over-quarter to $2.63B.

Based on Rock Springs Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.